Impact News +++ RAM: Plastik- statt Pappverpackung soll vor Betrug schützen (Heise) +++ CORSAIR Aktie +4,30%

ULTRAGENYX Aktie

>ULTRAGENYX Aktienkurs

18.2 EUR -8.5% (TradegateBSX)

Ask: 17.6 EUR / 910 Stück

Bid: 17.3 EUR / 930 Stück

Tagesumsatz: 1664 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ULTRAGENYX Aktie über LYNX handeln

Intraday

1 Jahr

>ULTRAGENYX Performance

1 Woche: -3,8%

1 Monat: -5,7%

3 Monate: -30,6%

6 Monate: -14,5%

1 Jahr: -52,2%

laufendes Jahr: +17,6%

>ULTRAGENYX Aktie

Name:

ULTRAGENYX PHARM. DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US90400D1081 / A1XCY0

Symbol/ Ticker:

UP0 (Frankfurt) / RARE (NASDAQ)

Kürzel:

FRA:UP0, ETR:UP0, UP0:GR, NASDAQ:RARE

Index:

Webseite:

https://www.ultragenyx.co..

Profil:

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. The com..
>Volltext..

Marktkapitalisierung:

1936.13 Mio. EUR

Unternehmenswert:

2307.31 Mio. EUR

Umsatz:

529.94 Mio. EUR

EBITDA:

-427.5 Mio. EUR

Nettogewinn:

-487.27 Mio. EUR

Gewinn je Aktie:

-4.99 EUR

Schulden:

725.34 Mio. EUR

Liquide Mittel:

178.44 Mio. EUR

Operativer Cashflow:

-374.53 Mio. EUR

Bargeldquote:

1.28

Umsatzwachstum:

14.46%

Gewinnwachstum:

1.58%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 72.117 USD.

Suchwörter:

ULTRAGENYX

Letzte Datenerhebung:

13.02.26

>ULTRAGENYX Kennzahlen

Aktien/ Unternehmen:

Aktien: 96.48 Mio. St.

Frei handelbar: 93.06%

Leerverk. Aktien: 9.43%

Rückkaufquote: -3.78%

Mitarbeiter: 1294

Umsatz/Mitarb.: 0.36 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 151.59%

Bewertung:

KGV: -

KGV lG: -

KUV: 3.9

KBV: 251.61

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 79.09%

Gewinnmarge: -91.95%

Operative Marge: -86.27%

Managementeffizenz:

Gesamtkaprendite: -42.5%

Eigenkaprendite: -325.76%

>ULTRAGENYX Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>ULTRAGENYX Chart & Kurs - NASDAQ

>ULTRAGENYX News

13.02.26 - 18:15	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
	RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027....

13.02.26 - 01:45	Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
	Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

13.02.26 - 00:48	Ultragenyx (RARE) Q4 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

13.02.26 - 00:45	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE (PR Newswire)
	NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980,......

13.02.26 - 00:24	Ultragenyx im Q4 2025: Umsatz übertrifft Erwartungen, doch Gewinnverfehlung belastet Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 22:09	Ultragenyx Pharmaceutical GAAP EPS of -$1.29 misses by $0.16, revenue of $207M beats by $5.14M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 22:06	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire EN)
	2025 total revenue of $673 million,Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million...

12.02.26 - 21:03	Investors in Ultragenyx Pharmaceutical Inc. Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - RARE (PR Newswire)
	NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead......

12.02.26 - 18:39	RARE Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE) (PR Newswire)
	Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc. Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) What: Securities fraud class action lawsuit filed Class Period: August 3, 2023, through December 26,......

12.02.26 - 04:09	RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class......

11.02.26 - 23:39	Ultragenyx Pharmaceutical Q4 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.02.26 - 19:12	Earnings Outlook For Ultragenyx Pharmaceutical (Benzinga)
	Importance Rank: 1 read more...

11.02.26 - 15:09	RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like......

10.02.26 - 13:12	INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - RARE (PR Newswire)
	SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, both dates inclusive (the "Class Period"), have until April 6, 2025 to......

09.02.26 - 09:31	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
	LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5......

09.02.26 - 09:27	RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the......

09.02.26 - 09:03	RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit (PR Newswire)
	NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025. A class action lawsuit has......

08.02.26 - 19:42	Quant snapshot: Manulife, KBC, Ambev lead strong buys as Ultragenyx, Atomera lag (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.02.26 - 04:18	Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE (PR Newswire)
	NEW ORLEANS, Feb. 6, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the......

06.02.26 - 17:45	Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE) (PR Newswire)
	PHILADELPHIA, Feb. 6, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Weiber lächeln, wenn sie grüßen. - Jean Paul

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram